Thermo Fisher Scientific announced on January 13 2026 that its pharmaceutical services division has won a series of contracts that will help clients relocate production from Europe or Asia to U.S. sites. CEO Marc Casper highlighted the deals in a briefing, noting that the company is “deepening its role as a trusted partner for U.S. manufacturing” and that the contracts are part of a broader reshoring strategy that the company has been pursuing for several years.
While Thermo Fisher did not disclose the exact number or dollar value of the contracts, the announcement confirms that the company will provide end‑to‑end support—including equipment procurement, installation, and long‑term service agreements—to enable clients to establish or expand U.S. manufacturing facilities. The contracts are expected to generate significant equipment sales and recurring service revenue, reinforcing the company’s one‑stop‑shop model and supporting margin expansion.
The new contracts dovetail with Thermo Fisher’s recent acquisition of Sanofi’s Ridgefield, New Jersey, manufacturing site, which the company has positioned as a key asset for on‑shore production. In addition, the firm’s collaboration with NVIDIA to embed AI into laboratory automation is expected to accelerate the deployment of advanced manufacturing technologies across its U.S. sites, further strengthening its competitive advantage in the biopharma sector.
Financially, the contracts are projected to add to the company’s already robust performance. In Q4 2024, Thermo Fisher reported revenue of $11.40 billion, up 0.5 % from $10.89 billion in Q4 2023, and an adjusted EPS of $6.10 versus $5.67 in the prior year. Adjusted operating margin expanded to 23.9 % from 23.4 % in Q4 2023, driven by higher‑margin service contracts and improved operational leverage. The new U.S. contracts are expected to sustain this upward trajectory by delivering both upfront equipment sales and long‑term service income.
Analysts have responded positively to the announcement, citing the company’s strong execution and the growing demand for U.S. biopharma manufacturing infrastructure. While no specific price movement is reported, the consensus view remains bullish, with analysts highlighting Thermo Fisher’s ability to capture recurring revenue streams and maintain margin expansion in a reshoring environment.
In summary, the new U.S. production contracts position Thermo Fisher to capitalize on a significant industry tailwind, reinforce its service‑centric business model, and support continued revenue and margin growth in the coming quarters.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.